

Phacilitate

PARTNERING FOR VACCINE EMERGING MARKETS

28-29 May 2014, Amsterdam

Colocated with:

Phacilitate

PARTNERING FOR PROTEIN
EMERGING MARKETS

Meeting local, regional and global vaccine needs

The most senior level forum for the world's leading vaccine strategists actively seeking partnerships. Opportunities in developed, emerging and developing countries are discussed and progressed by CEOs in an easy-to-reach location for all stakeholders.

For more information or to book your place, please visit www.biologicemergingmarkets.com/vaccines, call us on +44 (0)20 7384 7993, or email team@phacilitate.co.uk

Do you work for an emerging market pharma or biotech company, regulatory agency or other public sector body? You can attend this event free of charge! Contact Phacilitate today for more information.

www.biologicemergingmarkets.com

Meet 40+ speakers from
across the global vaccines
community, including:



Dr Surinder Singh, Director,
National Institute of Biologicals, (India)
(provisionally confirmed)



Dr Nora Dellepiane,
Coordinator, Regulatory Systems
Strengthening (RSS), WHO/EMP/RSS



Dr Suresh Jadhav, Executive
Director, Serum Institute of India



Lauren Franzel, Senior Specialist,
Policy & Market Shaping, GAVI Alliance



K.V. Balasubramaniam, Managing
Director, Indian Immunologicals Ltd



Dr Harish Iyer, Managing Director &
CEO, Shantha Biotechnics Ltd (India)



Dr Klaus Stöhr, Vice President &
Head, Global Policy, Novartis Vaccines &
Diagnostics



Dr Taras Nikolaev, Vice Director,
JSC Binnofarm (Russia)



Dr O. Mutlu Topal, Managing
Director, KEYMEN ILAC SANAYI VE
TICARET A.S. (Turkey)



Dr Peter H. Khoury,
Senior Program Officer,
Bill and Melinda Gates Foundation



Dr Alexander Precioso, Director
of the Division of Clinical Trials and
Pharmacovigilance, Instituto Butantan



Dr Do Tuan Dat, President &
Director General, VABIOTECH
(Vietnam)

**SEE INSIDE FOR THE FULL
PROGRAMME AND SPEAKER LIST.**

Register by 14th March
to save €200

SILVER SPONSOR

SPONSORS

EVENT PARTNERS



Arbovax®

International
Society for
VACCINES

ISBioTech™
International Society for BioProcess Technology



BioPartner

Learn from the experiences of 40+ high profile speakers representing all the key emerging vaccine markets as well as major NGOs:

Dr Surinder Singh, Director, National Institute of Biologicals, (India) (provisionally confirmed)

Dr Nora Dellepiane, Coordinator, Regulatory Systems Strengthening (RSS), WHO/EMP/RSS

Dr Suresh Jadhav, Executive Director, Serum Institute of India

Dr Peter H. Houry, Senior Program Officer, Bill and Melinda Gates Foundation

Lauren Franzel, Senior Specialist, Policy & Market Shaping, GAVI Alliance

Dr Alexander Precioso, Director of the Division of Clinical Trials and Pharmacovigilance, Instituto Butantan (Brazil)

K.V. Balasubramaniam, Managing Director, Indian Immunologicals Ltd

Dr Harish Iyer, Managing Director & CEO, Shantha Biotechnics Ltd (India)

Dr Do Tuan Dat, President & Director General, VABIOTECH (Vietnam)

Dr Charung Muangchana, MD, PhD, Director, National Vaccine Institute (NVI) (Thailand)

Dr Aydar A. Ishmukhametov, Director of Federal State Unitary Enterprise on Manufacture of Bacterial & Viral Preparations, FSUE of Chumakov IPVE (Russia)

Dr Klaus Stöhr, Vice President & Head, Global Policy, Novartis Vaccines & Diagnostics

Ann M. Ginsberg, MD, PhD, Chief Medical Officer, Aeras

Dr Taras Nikolaev, Vice Director, JSC Binnofarm (Russia)

Haluk Omer Karabatak, South Eastern Europe Lead, Pfizer Pharmaceuticals

Alireza Gholami, Head, Viral Vaccines Production Unit, Production Complex, Institute Pasteur of Iran

Dr Inca Kusters, Director External R&D, Sanofi Pasteur

Frank Appel, Senior Manager, Europe Vaccines Segment, Merck Millipore

Graham Clarke, CEO & Director, ImmBio

Dr Reinhard Glüeck, Chief Scientific Officer, Zydus Cadila

Dr Michael P McCarthy, Director, Infectious Disease & Vaccines & Head, Vaccine Platform Group, Medimmune Inc

Dr Mark Feinberg, Vice President & Chief Public Health & Scientific Officer, Merck & Co (Provisionally confirmed)

Jack Zhang, China Country Program Director, PATH

Odile Leroy, Executive Director, European Vaccine Initiative

Dr Jon Kim Andrus, Deputy Director, PAHO/WHO

Malcolm Thomas, President & Chief Executive Officer, Arbovax, Inc

Dr O. Mutlu Topal, Managing Director, KEYMEN ILAC SANAYI VE TICARET A.S. (Turkey)

Igor Krasilnikov, Deputy Director of International Relations & Innovations, St. Petersburg Institute of Vaccines and Sera (Russia)

Dr George Robertson, Senior Technical Advisor, PATH

Dr Jeffrey Ulmer, Global Head, External Research, Novartis Vaccines and Diagnostics

Dr Allan P. Jarvis, President, JBBDA, LLC

Dr Manoj Kumar, Associate Director, R&D, MSD Welcome Trust Hilleman Labs

Susan Liu, Deputy Senior Programme Manager, Vaccines Markets, Clinton Health Access Initiative Inc

Dr Jerald Sadoff, Head, Early Development, Crucell Vaccine Institute

Dr Marc Laforce, Former Director at Meningitis Vaccine Project, PATH

Dr Timos Papagatsias, Director, EU Life Sciences, Fuld & Company



The world's emerging vaccine market leaders brought together for 2 days in Europe

This event is all about partnering.

It gives you the chance to have numerous 1-to-1 meetings with vaccine industry leaders from across the globe in just 2 days:

- Pre-event online networking tool enabling you to contact your fellow attendees from 4 weeks prior to the event and pre-arrange meetings for onsite
- 10 hours set aside during the agenda for meetings
- 1-to-1 meeting booths in the exhibition area
- Buffet breakfasts and lunches, extended refreshment breaks and an evening cocktail reception: All ideal for informal discussions with established and new contacts.
- **...AND NEW FOR 2014!** Dedicated Speed Networking sessions during the morning coffee break on each day of the event.

"The 2013 Phacilitate Conference in Berlin included high quality delegates and very focused topic presentations. It was a very informative conference with lots of networking and information directly applicable to my role"

Frank Appel, Senior Manager, Europe, Vaccines Segment, Merck Millipore

PLUS! Meet and network with the speakers and delegates for the Partnering for Protein Emerging Markets event, including representatives of many companies with interest and activities in both vaccine and therapeutic protein spheres.

Phacilitate is committed to ensuring that you make the contacts that you need to take your business forward. Our pre-event online networking tool is guaranteed to be the quickest and easiest way to build your network.

This secure online resource allows you to interact with attendees before and during the event. It's the ideal way to connect with potential partners, solution providers and customers.

Search the entire attendee list for key contacts and send meeting requests to delegates, exhibitors, speakers, sponsors and press. Prearrange mutually convenient times to get together during the event.

This networking tool will help you:

1. Identify contacts before the event and meet the right people on the day
2. Start the conversation before the event and continue it afterwards
3. Promote your work and share ideas on the live discussion board
4. Speak freely - the network is only open to your fellow attendees
5. Connect on the website, on mobile, on twitter or by SMS text message

The system will be live for 4 weeks before the event. All attendees will receive login details and their access code by email once they have registered. If you have any questions contact us at team@phacilitate.co.uk.

Register early to benefit from the early bird rate, and to ensure you gain maximum benefit from online partnering – see the back page for details

Sponsorship and exhibition opportunities

Phacilitate's Partnering for Vaccine Emerging Markets meeting is designed for senior level business and R&D leaders from across the global sector. It provides a great opportunity for companies who supply manufacturing, consultancy and R&D services to vaccine developers to raise their profile and develop new business on a global basis.

For more information and to discuss options, call Michael Adeniya on +44 (0)20 7384 8051 or email team@phacilitate.co.uk.

Ideal for informal discussions with established and new contacts.



"Unique forum for local and global biopharma companies to discuss partnership opportunities aimed at growing market access within the Emerging Markets"

Samuel Ang, Abbott

For more information or to book your place, please visit www.biologicemergingmarkets.com, call us on +44 (0)20 7384 7993 or email team@phacilitate.co.uk.

DAY I - Wednesday May 28th 2014

7.30 Registration, buffet breakfast & 90 minutes of 1-to-1 partnering in the exhibition area

GAVI, PAHO AND THE CLINTON HEALTH ACCESS INITIATIVE ARE SPEAKING THIS MORNING

Morning plenary session

MACRO TRENDS AND DYNAMICS IN THE GLOBAL VACCINE MARKETPLACE

9.00 CHAIR'S INTRODUCTION

Dr Klaus Stöhr, Vice President & Head, Global Policy, Novartis Vaccines & Diagnostics

9.05 OPENING PRESENTATION

Shaping the future vaccine markets of emerging countries: growth opportunities and pitfalls

- Overview of recent developments in the vaccine markets in emerging countries
- Growth opportunities for local and global players
- Key points to consider moving forward

Dr Timos Papagatsias, Director, EU Life Sciences, Fuld & Company

9.25 Questions & discussion

9.30 PRESENTATIONS & MULTIPLE STAKEHOLDER ROUNDTABLE DISCUSSION

How is vaccine manufacturing capacity and its utilization evolving globally? And does it tally with demand?

- Analysing worldwide trends in the growth of vaccine manufacturing capabilities, and of supply and demand
 - What product mix are vaccine manufacturers in emerging markets aiming for?
- Addressing the issue of future oversupply: What are the repercussions of this for developed and emerging market manufacturers?
 - To what extent should emerging market manufacturers shift from traditional vaccines to novel combination vaccines? What can/should be done to ensure adequate ongoing supply of traditional vaccines to local markets? (Eg. of DPT vaccine in India)

Panellists:

Dr Peter H. Khoury, Senior Program Officer, Bill and Melinda Gates Foundation
Dr Suresh Jadhav, Executive Director, Serum Institute of India
K.V. Balasubramaniam, Managing Director, Indian Immunologicals Ltd
Dr Jon Kim Andrus, Deputy Director, PAHO/WHO

10.25 PRESENTATIONS & PANEL DISCUSSION

Western pharma priorities and collaborative strategies

- How are collaborative models and priorities changing with emerging market industry players and other stakeholders (eg. NGOs)?
- How are lingering IP-related concerns being addressed?

Panellists:

Dr Inca Kusters, Director External R&D, Sanofi Pasteur
Haluk Omer Karabatak, South Eastern Europe Lead, Pfizer Pharmaceuticals
Dr Michael P McCarthy, Director, Infectious Disease & Vaccines & Head, Vaccine Platform Group, Medimmune Inc

11.15 Morning coffee & SPEED NETWORKING in the exhibition area

11.55 PRESENTATION & PANEL DISCUSSION

Ensuring the future affordability of vaccines: How to sustain coverage of much needed vaccines against diseases such as rotavirus in countries graduating from GAVI support?

- What will be the roll of tiered pricing moving forward? What is affordable in reality to these countries?

Panellists:

Lauren Franzel, Senior Specialist, Policy & Market Shaping, GAVI Alliance
Dr Mark Feinberg, Vice President & Chief Public Health & Scientific Officer, Merck & Co (Provisionally confirmed)

12.30 PRESENTATIONS & PANEL DISCUSSION

What will be the impact of IPV on the emerging market landscape as a whole over the next few years?

- How to make disease eradication a viable business case for industry?

Panellists:

Dr Klaus Stöhr, Vice President & Head, Global Policy, Novartis Vaccines & Diagnostics
Dr Suresh Jadhav, Executive Director, Serum Institute of India
Susan Liu, Deputy Senior Programme Manager, Vaccines Markets, Clinton Health Access Initiative Inc

1.05 PRESENTATIONS & PANEL DISCUSSION

What can emerging market vaccine companies bring to Western markets in the foreseeable future?

- What are the key obstacles to their entry today and how are they seeking to address them?

Panellists:

Dr Harish Iyer, Managing Director & CEO, Shantha Biotechnics Ltd (India)
Dr Reinhard Glüeck, Chief Scientific Officer, Zydus Cadila (India)

1.30 Buffet lunch and 70 minutes of 1-to-1 partnering in the exhibition area

Followed by your choice of 2 parallel breakout sessions

MEDIA PARTNERS



“Unique and very useful event. The excellent mix of DC and MNC manufacturers with regulators and funders was exceptionally useful”

Dr George Robertson, PATH

“This was a very intense 2 days with very relevant content and high quality attendees”

Malcolm Thomas, Arbovax

For more information or to book your place, please visit www.biologicemergingmarkets.com, call us on +44 (0)20 7384 7993 or email team@phacilitate.co.uk.

Register by 14th March to save €200
Visit www.biologicemergingmarkets.com/vaccines for the full programme

Focus session 1

MAJOR GLOBAL HEALTH THREATS AT THE CROSSROADS – DEFINING THE FUTURE ROLE FOR PROPHYLACTIC VACCINES IN COUNTERING:

- Malaria
- Dengue fever
- TB

2.40 CHAIR'S INTRODUCTION

Dr Jerald Sadoff, Head, Early Development, [CruCell Vaccine Institute](#)

Malaria and dengue fever: Case studies, followed by panel discussion

- Clinical development updates on the most advanced product candidates
- Is the big picture changing? What role do the various stakeholders see for prophylactic vaccines alongside therapeutic interventions and vector control strategies moving forward?

2.45 CASE STUDY 1

Malaria

Odile Leroy, Executive Director, [European Vaccine Initiative](#)

3.00 CASE STUDY 2

Dengue vaccine project at Instituto Butantan

Dr Alexander Precioso, Director of the Division of Clinical Trials & Pharmacovigilance, [Instituto Butantan \(Brazil\)](#)

3.15 CASE STUDY 3

Dengue fever

Malcolm Thomas, President & Chief Executive Officer, [Arbovax, Inc](#)

3.30 PANEL DISCUSSION

TB: Case study, followed by panel discussion

- Clinical development update
- Proposed new paradigm for vaccine "up-selection" to aid global portfolio management
- Correlates of risk and protection: approaches to discovery and validation
- What's coming next for TB vaccine R&D funding?

3.50 CASE STUDY

Ann M. Ginsberg, MD, PhD, Chief Medical Officer, [Aeras](#)

4.05 PANEL DISCUSSION

4.20 Afternoon tea & SPEED NETWORKING in the exhibition area

OR Focus session 2

ANALYSING SUCCESSFUL TECHNOLOGY TRANSFER EXAMPLES: DEFINING A RECIPE FOR THE 'WIN-WIN' SITUATION

2.40 CHAIR'S INTRODUCTION

How have vaccine technology transfer trends between developed and emerging markets evolved over recent years?

Dr Allan P. Jarvis, President, [JBBDA, LLC](#)

Case studies of successful collaborations involving vaccines for key public health threats: What can we learn from them?

3.05 CASE STUDY - Cholera

Dr Harish Iyer, Managing Director & CEO, [Shantha Biotechnics Ltd](#)

3.20 CASE STUDY

- Technology transfer to Iran as a developing country:
 - A streamlined procedure?
- Departure: Pertinent ground for technology transfer; government or private sector?
- Connections: Establishing developed-developing-developing country, two or three partite connections?
- Destinations: Observe as far as possible, make it possible

Alireza Gholami, Head, Viral Vaccines Production Unit, Production Complex, [Institute Pasteur of Iran](#)

3.35 CASE STUDY

Dr Reinhard Glüeck, Chief Scientific Officer, [Zydus Cadila](#)

3.50 QUESTIONS FOR THE SPEAKERS & PANEL DISCUSSION

What will be the next steps in the continuing evolution of the Western-emerging market tech transfer model?

Panelist:

Dr Manoj Kumar, Associate Director; R&D, [MSD Wellcome Trust Hilleman Labs Pvt Ltd](#)

4.20 Afternoon tea & SPEED NETWORKING in the exhibition area

Afternoon plenary session

REGIONAL SPOTLIGHT: RUSSIA & TURKEY

- Understanding supply and demand in the vaccine markets nationally and regionally

4.55 RUSSIA AND TURKEY: PROFILING VACCINE DEMAND, SUPPLY AND THE ASPIRATIONS OF THE LOCAL INDUSTRY

- Defining each country's vaccine needs, priorities and opportunities in terms of:
 - o market size and expected growth
 - o prevalence of current and potential future vaccine-preventable diseases
 - o bioprocessing capacity, technological capability, and manufacturing sector characteristics (eg. the balance of public versus private players)
 - o vaccine reimbursement scenario
 - o vaccine delivery infrastructure
 - o regulatory environment
 - o inclusion of multinational vaccine companies
 - o local, regional and global activities and aspirations of local vaccine companies

Panelists:

Igor Krasilnikov, Deputy Director of International Relations & Innovations, [St. Petersburg Institute of Vaccines and Sera \(Russia\)](#)

Dr Taras Nikolaev, Vice Director, [JSC Binnofarm \(Russia\)](#)

Dr Aydar A Ishmukhametov, Director of Federal State Unitary Enterprise on Manufacture of Bacterial and Viral Preparations, [FSUE of Chumakov IPVE \(Russia\)](#)

Dr O. Mutlu Topal, Managing Director, [KEYMEN ILAC SANAYI VE TICARET A.S. \(Turkey\)](#)

Haluk Omer Karabatak, South Eastern Europe Lead, [Pfizer Pharmaceuticals](#)

6.00 Close of day 1, followed by a cocktail reception in the exhibition area. 90 minutes of networking in a business-focused, but informal environment

For more information or to book your place, please visit www.biologicemergingmarkets.com, call us on +44 (0)20 7384 7993 or email team@phacilitate.co.uk.

DAY 2 - Thursday May 29th 2014

7.30 Registration, buffet breakfast & 90 minutes of 1-to-1 partnering in the exhibition area

SOUTH EAST ASIAN AND LATIN AMERICAN MARKETS ANALYSED IN-DEPTH TODAY

Morning plenary session

EXAMINING THE BROADER REPERCUSSIONS OF GLOBAL VACCINE REGULATORY EVOLUTION

9.00 CHAIR'S INTRODUCTION

9.05 Presentations & roundtable discussion

How will changes to the WHO's prequalification procedure impact the vaccine world at large?

• **WHO perspective**

- o What are the major regulatory challenges faced in the vaccine arena?
- o How and why are the regulatory approaches changing?
- o How and why is prequalification changing?
- o What efforts are being made to accelerate the registration and prequalification approval processes?

• **Case studies: How are emerging market companies that have achieved WHO prequalification planning for the future?**

- o How are their global vaccine supply strategies developing?
- What will be the impact on the Chinese vaccine industry as a whole of the recent pre-qualification of CNBG's JE vaccine?
 - o How are other Chinese companies seeking to follow this lead?
- Delving into the specific repercussions of the changes from both developed and emerging market manufacturer perspectives. (Eg. How will regulation concerning variations play out?)

Speakers to include:

Dr Nora Dellepiane, Coordinator Regulatory Systems Strengthening (RSS), WHO/EMP/RSS

Jack Zhang, China Country Program Director, PATH

10.25 SHORT PRESENTATIONS & REGULATOR/INDUSTRY ROUNDTABLE DISCUSSION

How to streamline vaccine regulation in key emerging markets such as India, China and Brazil?

- Where are the opportunities for increased harmonisation on both manufacturing and clinical fronts?
- Defining and addressing the specific challenges in conducting clinical trials in India, including liability around adverse events
- Are there changes afoot in China to make it easier for foreign companies to engage?

Speakers to include:

Dr Surinder Singh, Director, National Institute of Biologicals (India) (Provisionally confirmed)

Dr Alexander Precioso, Director of the Division of Clinical Trials and Pharmacovigilance, Instituto Butantan (Brazil)

11.10 What is the future for joint review of clinical protocols? What lessons can we take from recent successes?

Dr Marc Laforce, Former Director at Meningitis Vaccine Project, PATH

11.30 Morning coffee & SPEED NETWORKING in the exhibition area

Followed by your choice of 2 parallel breakout sessions:

Focus session 1

DRIVING COST-EFFECTIVE TECHNOLOGIES INTO EMERGING MARKETS: PART 1 - VACCINE MANUFACTURING

CHAIR'S INTRODUCTION

Dr Inca Kusters, Director External R&D, Sanofi Pasteur

12.10 Affordable innovation

Graham Clarke, CEO & Director, ImmBio

Tech Spotlight: Which bioprocessing technologies and platforms have the potential to be genuinely disruptive in terms of delivering significant cost reductions and/or technical advancement to emerging market manufacturers?

12.30 Synthetic vaccine manufacturing technologies

Dr Jeffrey Ulmer, Global Head, External Research, Novartis Vaccines and Diagnostics

12.45 Overcoming challenges of hcDNA removal in vaccine manufacturing

Frank Appel, Senior Manager, Europe Vaccines Segment, Merck Millipore

1.00 Presentation reserved

1.15 Questions for the speakers & panel discussion

1.30 Buffet lunch & 65 minutes of 1-to-1 partnering in the exhibition area

OR WORKING LUNCH

(Extremely informal discussion-based session for a maximum of 12 participants)
Capacity building and design/execution of multi-vaccine facilities in emerging market countries

OR

Focus session 2

REGIONAL SPOTLIGHT: BEYOND BRIC - SOUTHEAST ASIA

• Understanding supply and demand in the vaccine markets nationally and regionally

12.10 Indonesia, Thailand, Malaysia and Bangladesh: Profiling vaccine demand, supply and the aspirations of the local industry

- Defining each country's vaccine needs, priorities and opportunities in terms of:
 - o market size and expected growth
 - o prevalence of current and potential future vaccine-preventable diseases
 - o bioprocessing capacity, technological capability, and manufacturing sector characteristics (eg. the balance of public versus private players)
 - o vaccine reimbursement scenario
 - o vaccine delivery infrastructure
 - o regulatory environment
 - o inclusion of multinational vaccine companies
 - o local, regional and global activities and aspirations of local vaccine companies

Speakers to include:

Dr Do Tuan Dat, President & Director General, VABIOTECH (Vietnam)
Charung Muangchana, MD, PhD, Director, National Vaccine Institute (NVI) (Thailand)

1.30 Buffet lunch & 65 minutes of 1-to-1 partnering in the exhibition area

OR WORKING LUNCH

(Extremely informal discussion-based session for a maximum of 12 participants)
Capacity building and design/execution of multi-vaccine facilities in emerging market countries

Visit www.biologicemergingmarkets.com/vaccines for the full programme

Followed by your choice of 2 parallel breakout sessions:

Develop new partnerships with leading emerging market companies

Focus session 1

DRIVING COST-EFFECTIVE TECHNOLOGIES INTO EMERGING MARKETS: PART 2 – THERMOSTABLE VACCINE FORMULATIONS

Tech Spotlight: Cutting-edge thermostable technology platforms in development (including adjuvant-related examples)

2.35 Case study 1

Dr Manoj Kumar, Associate Director, R&D, MSD Wellcome Trust Hilleman Labs

2.50 Case study 2

Susan Liu, Deputy Senior Programme Manager, Vaccines Markets, Clinton Health Access Initiative Inc

3.05 Case study 3

Presentation reserved

3.20 QUESTIONS FOR THE SPEAKERS & PANEL DISCUSSION Who will pay for these technologies in the developing world?

- How to incentivise emerging market manufacturers to adopt new technologies that increase benefit, but also the cost of goods?

3.45 Afternoon tea & 35 minutes of 1-to-1 partnering in the exhibition area

OR

Focus session 2

REGIONAL SPOTLIGHT: BEYOND BRIC - LATIN AMERICA

- Understanding supply and demand in the vaccine market nationally and regionally

2.35 CHAIR'S INTRODUCTION

Dr Jon Kim Andrus, Deputy Director, PAHO/WHO

2.40 Profiling vaccine demand, supply and the aspirations of the local industry

- Defining vaccine needs, priorities and opportunities in terms of:
 - o market size and expected growth
 - o prevalence of current and potential future vaccine-preventable diseases
 - o bioprocessing capacity, technological capability, and manufacturing sector characteristics (eg. the balance of public versus private players)
- o vaccine reimbursement scenario
- o vaccine delivery infrastructure
- o regulatory environment
- o inclusion of multinational vaccine companies
- o local, regional and global activities and aspirations of local vaccine companies

The speakers for this session will be announced shortly online at www.biologicemergingmarkets.com

3.45 Afternoon tea & 35 minutes of 1-to-1 partnering in the exhibition area

Afternoon plenary session

WHAT ARE THE KEY "DO'S AND DON'TS" WHEN IT COMES TO SUCCESSFULLY SUPPLYING VACCINES TO EMERGING MARKETS?

4.20 PRESENTATIONS & PANEL DISCUSSION

A PATH-led overview of vaccine success stories from the perspectives of emerging market manufacturers, including vaccines against:

- Meningitis
- Japanese encephalitis
- Rotavirus

Chair:

Dr George Robertson, Senior Technical Advisor, PATH

Panellists:

Jack Zhang, China Country Program Director, PATH

Dr Marc Laforce, Former Director at Meningitis Vaccine Project, PATH

5.30 CLOSE OF PHACILITATE PARTNERING FOR VACCINE EMERGING MARKETS 2014

13 countries are represented on the speaker panel so far, giving you the perfect chance to network with leaders from across the globe in a cost- and time-effective way:

- India • Russia • China • Turkey • Brazil • Vietnam • Iran

PRE-EVENT ONLINE PARTNERING

10 hours set aside for 1-to-1 meetings



Visit www.biologicemergingmarkets.com/vaccines for the full programme

For more information or to book your place, please visit www.biologicemergingmarkets.com, call us on +44 (0)20 7384 7993 or email team@phacilitate.co.uk.

Register by 14th March to save €200 on the standard industry rate!

Please register online at www.biologicemergingmarkets.com

Rates:

2 day conference @ early bird rate 2 (valid until 14th March)	
Industry:	€1,865.00 / £1,545.00 / \$2,485.00
Academic/ Government/ Not-for-profit	€1,085 / £895.00 / \$1,445.00
Standard 2 day rate (from 15th March onwards)	
Industry:	€2,065.00 / £1,715.00 / \$2,755.00
Academic/ Government/ Not-for-profit:	€1,185.00 / £985.00 / \$1,585.00

** 21% Dutch VAT will be added to all fees.

You will receive a VAT invoice on receipt of your registration

For information on:

- Small company rates
- Group discounts
- The rate for 1-day attendance

Please email team@phacilitate.co.uk or call +44 (0)20 7384 7993

Silver sponsor:



Merck Millipore, the Life Science division of Merck KGaA, offers a comprehensive portfolio of products and services to make, purify, formulate and assure the quality and safety of drug production. With unrivalled breadth at every step in the process, we can improve productivity, reduce risk, cost, and get your drug to market faster.

www.merckmillipore.com

Sponsors:



ImmBio is developing next-generation vaccines targeting a number of serious infectious diseases, based on its proprietary novel ImmBioVax™ technology. During vaccine production, ImmBioVax™ mimics the

normal immune response to a pathogen. This process produces vaccines containing multi-protein complexes that are designed to elicit broad-based priming of the immune system to block subsequent infection by multiple strains of the pathogen. ImmBio is developing vaccines against a number of diseases, including invasive meningococcal disease, tuberculosis and invasive pneumococcal disease.

www.immbio.com



ArboVax®

ARBOVAX™ Inc. is engaged in the development of vaccines against mosquito-borne diseases that collectively infect over 300 million

people annually. Mosquito-borne viruses provide some of the most important examples of emerging and resurging diseases of global significance including Dengue Fever, Japanese Encephalitis, West Nile, Chikungunya and Yellow Fever. The company currently is preparing for a phase I trial of its Dengue Fever vaccine with several other targets in the pipeline.

www.arboVax.com

The venue:

The venue hotel in Amsterdam will be announced very shortly on the event website - www.biologicemergingmarkets.com.

Accommodation: The conference fee does not include accommodation, but we have negotiated substantially discounted rates for all attendees at the venue hotel. For more information please visit the event website.

Documentation: The conference documentation will be available on our website after the event for those individuals who cannot attend in person. If you are interested in receiving information on contents and cost in due course, please e-mail team@phacilitate.co.uk

Amendments to our mailing list: If you would prefer not to receive any further materials from Phacilitate, please contact us and let us know your name, company and location. We guarantee you will be removed from our database immediately. Please also inform us in the same way if your details have changed or are currently incorrect. You can let us know by phone (+44 (0)20 7384 8048), e-mail (team@phacilitate.co.uk), fax (+44 (0)20 7384 8047) or mail (Phacilitate Limited, 4th Floor, Fulham Green, Bedford House, 69-79 Fulham High Street, London SW6 3JW, UK).

Event partners:



The International Society for BioProcess Technology (ISBioTech) was established to advance process and analytical techniques, plus make the latest bioprocess technology readily available to

those developing and producing biopharmaceuticals worldwide. The society is dedicated to the scientists and engineers who have day-to-day responsibility for creating and managing scalable and reproducible processes, as well as the assays needed to insure indisputable quality. Through networking events, the society's sister publications - the BioProcessing Journal and its Techno-Blast mass emails, biotech professionals can access and share the techniques and best practices needed for safe, effective, and consistent products.



International Society for Vaccines is an organization that engages, supports and sustains the professional goals of a diverse membership in all areas relevant to vaccines. With the successful conclusion of the 2013 Vaccine and ISV Annual Congress and ISV General Meeting, a new set of elected officials to the Executive Board will guide the Society for the next two years. Goals are focused on expanding the membership database and the enhanced attendance at the Annual Congresses. In addition, an out research initiative has begun to partner with organizations to promote ISV activities, such as Phacilitate's Conference on Partnering for Vaccines Emerging Markets 2014.

www.isv-online.org



Asia Pacific Paediatric Association

The essential objectives of APPA, as set out in its Constitution, are: "Promotion of research in all aspects of Paediatrics, dissemination of knowledge in child health, organisation of an Asian Congress of Paediatrics triennially and enhancement of National Paediatric meetings."

<http://a-p-p-a.org/>



BioPartner UK is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's UK Delegations promote the UK presence at major international biopharma

conferences, and all UK-based companies can access government grants and heavily discounted entry fees. BioPartnership programme members benefit from partnerships with Government and Network alliances, industry expertise, and cost savings through bulk purchasing; including policy updates and lobbying efforts of the UK Biotechnology Association.

<http://biopartner.co.uk/events.php#event:704>



European Association of Pharma Biotechnology (EAPB) is the representative of pharmaceutical biotechnology in Europe, dedicated to advancement of biotechnology in pharmaceutical sciences, specifically as applied to medicinal drugs, industrial materials, processes, products and associated issues.

Conference "Science to Market"

Special Interest Groups "Regenerative Medicine" and "Regulatory Aspects for Biopharmaceuticals"

www.eapb.org

For more information or to book your place, please visit www.biologicemergingmarkets.com, call us on +44 (0)20 7384 7993 or email team@phacilitate.co.uk.